MESSAGE FROM THE DIRECTOR
Stan Gerson, MD
Director, Case CCC
On Thursday, April 19, the directors of the NCI-designated cancer centers, including myself, met with Harold Varmus to review priorities and topics of special interest to the NCI. The meeting covered a number of items of general interest to our Cancer Center membership, which I will briefly summarize below. Should any interest you, please email me to review them further.
- Budget: The general impression is to expect a flat budget for the next five years. This includes cancer centers, and the expectation that three to five additional cancer centers will join as NCI-designated over the next five years. The budgets of the additional centers will likely reduce available funds to existing centers.
- Payline: The current sliding scale of secondary NCI review of grants scoring between 5% and 12% has resulted in the appropriate frequency of funded grants, i.e. a grant at 7% is more likely to be funded than one at 12%, but some at 5% and most at 12% will not be funded.
- NCI-Frederick: The NeXT program and other contract work at NCI-Frederick is being reorganized. We were encouraged to submit applications to the various programs at this facility. In subsequent newsletters we will provide more detail of opportunities.
- Team Science: The NCI views teams as the origins of some of its greatest impact science and clinical advances. NCI encourages cancer centers to support and catalyze team science. A report from the Team Science retreat that I attended will be forthcoming. Future multi-investigator grants will request a description of efforts to promote team science by the PI and the institution.
The two major areas of discussion at the meeting were Genomics and Cancer Care, presented by Barbara Wold, NCI; Arul Chinnauiyan, University of Michigan; Bill Pao, Vanderbilt University; and Elaine Mardis, Washington University. Some key points included:
- Cancer genomics results in a very complex characterization of individual tumors- each is unique
- Driver genes become drug targets but is a small subset of informative mutations
- Tumor response will ultimately depend on the complex combinatorial disregulation that results in tumor growth and drug response
- NCI is considering requiring that genomic analysis be pursued in all NCI supported clinical studies of human cancers
- Open discussion: which patients would benefit most- diagnosis or at relapse
- How would therapeutics be changed- if patients need to travel to the site of an open drug trial, this may be untenable. This suggests the concept of "just in time" IRB approval so that the drug is shipped to the patient, not the patient traveling to the drug.
- Michigan has implemented a genomics tumor board to provide advice on how genomics can inform clinical drug decision making. This panel includes genomics and disease experts, ethicists and genetic counselors.
Many issues remain:
- Will this approach improve patient outcomes?
- How will patients access new drugs?
- What are the appropriate decision tree algorithms?
- How should the rapid upgrades on sequencing equipment be managed?
- Will NCI or commercial partners drive the technology?
The Case CCC has assembled over 25 members to develop a position paper on Cancer Genomics. This effort is now in its final stages. An Executive Summary will be forthcoming in the next 2-3 weeks and will be posted for comments in this newsletter. Other topics from the NCI Directors retreat will be forthcoming.
CASE CCC IN THE NEWS
IMRI is Key Tool in Brain Surgery
Canton Repository - Apr 23, 2012
Using IMRIS lengthens surgery by up to an hour, but it can save patients from repeated operations, said brain surgeon Michael Vogelbaum...
UH Testing Non-invasive Way to Check for Colon Cancer
WKYC - Apr 19, 2012
...sDNA is a novel test that detects colon cancer in its earliest stages, based on analysis of stool DNA. Developed in the laboratory of Sanford Markowitz, MD, PhD, oncologist with the UH Seidman Cancer Center and Professor at Case Western Reserve University School of Medicine, sDNA is a recommended screening by the American Cancer Society. "Colon cancer is the second leading cause of cancer deaths in the United States but is a preventable disease," says Gregory Cooper, MD, Co-Program Leader for Cancer Prevention ...
University Hospitals Case Medical Center's Seidman Cancer Center is hosting IMAGINE Benefit
Broadway World - Apr 18, 2012
... "The support of The Brian Werbel Memorial helps our nationally recognized cancer center in its mission to translate scientific discovery rapidly to patient care," said Stan Gerson, MD, Director of the UH Seidman Cancer Center.
Dr. Dreicer on Sequencing MDV3100 and Abiraterone
OncLive - Apr 17, 2012
Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute at the Cleveland Clinic, discusses the sequencing ...
Genetic Profile IDs Leukemia Patients for High-dose Chemotherapy
Oncology Nurse Advisor - Apr 17, 2012
Hillard M. Lazarus, MD, of the Seidman Cancer Center at University Hospitals Case Medical Center in Cleveland, Ohio, and colleagues performed a mutational ...
New Radiation Therapy Reduces Treatment of Gynecologic Cancers from 5 Weeks to 3 Days
EurekAlert - Apr 17, 2012
Dr. Charles Kunos, who co-authored the article, said the radiation therapy machine "looks like a robot you would make cars with, and targets specific cancer ...
Results of Brain Cancer Treatment Vaccine Continue to be Promising
Plain Dealer - Apr 17, 2012
Earlier this year, Robertson returned to Cleveland for a follow-up appointment with neurosurgeon Dr. Andrew Sloan, director of the Brain Tumor and Neuro-Oncology Center at University Hospitals Case Medical Center who oversaw UH's participation in the vaccine's clinical trial...
MARK YOUR CALENDARS
Cancer Center Seminar Series: Variant Enhancer Loci in Cancer
Friday, April 27
Please join us April 27 for the next Cancer Center Seminar Series where Dr. Peter Scacheri will present Variant Enhancer Loci in Cancer. He will show data indicating that alterations in epigenetic marks at gene enhancer elements are a driving force in colon carcinogenesis. Furthermore, these enhancer alterations define a novel epigenetic signature of colon cancer.
Dr. Scacheri is Assistant Professor in the Department of Genetics and Genome Sciences at CWRU, and a member of the Case CCC. His research team has been instrumental in the utilization and advancement of cutting-edge genomic technologies to understand the molecular basis of human diseases, including cancer.
Second Annual Personalized Healthcare Summit
Registration is open for the Cleveland Clinic 2012 Personalized Healthcare Summit, Thursday, May 31 at the InterContinental Hotel and Conference Center. The purpose of this event is to educate about clinically-relevant applications of personalized healthcare, the research behind these discoveries, and solutions to incorporate personalized healthcare into clinical practice. The day-long Summit CME event will consist of a series of talks, panels and interactive presentations by expert clinicians from a variety of medical settings. The long term goal is to provide attendees with the knowledge to improve patient health and wellness by incorporating the pro-active and preventive principals of personalized healthcare.
Ninth International Conference of the Society for Integrative Oncology
The Society for Integrative Oncology (SIO) is happy to announce the Call for Online Submission of abstracts for oral presentation, posters, and workshops at the Ninth International Conference of the Society for Integrative Oncology, to be held in Albuquerque, NM October 8-10, 2012. The theme of the conference is "Honoring Diversity in Cancer Prevention and Control".
SIO will grant Early Investigator Awards to early career investigators who submit New Original Research for the conference. To qualify for consideration for an Early Investigator Award, the first author must be a graduate student, post-doctoral fellow, resident, or fellow.
The deadline for submission of abstracts and workshops is Friday, June 1.
AACR Awards Honoring Scientific Achievement
The American Association for Cancer Research (AACR) has released a call for nominations for the following opportunities:
DOD Lung Cancer Research Program
- AACR Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen for the Cure®: For an investigator of no more than 50 years of age whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment or prevention of breast cancer.
Deadline: May 16
- AACR Distinguished Lectureship in Breast Cancer Research: Recognizes outstanding science that has inspired or has the potential to inspire new perspectives on the etiology, diagnosis, treatment or prevention of breast cancer.
Deadline: May 16
- AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research: For seminal contributions to the field of cancer prevention.
Deadline: June 20
- AACR Award for Distinguished Lecture on the Science of Health Disparities, funded by Susan G. Komen for the Cure®: For an investigator whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment or prevention of cancer health disparities.
Deadline: June 20
Applications for the Lung Cancer Research Program (LCRP)are being solicited by the Assistant Secretary of Defense for Health Affairs, Defense Health Program. The goal of the FY12 LCRP is to eradicate deaths from lung cancer to better the health and welfare of the military and the American public. As such, the LCRP will support and integrate research from multiple disciplines for risk assessment, early detection, diagnosis, prevention, cure, and control of lung cancer.
Damon Runyon-Rachleff Innovation Award
- The LCRP Idea Development Award mechanism is being offered for the first time in FY12. This award is designed to promote new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation.
Pre-Application Deadline: May 30
Application Deadline: September 20
- The LCRP Translational Research Partnership Awardmechanism is being offered for the first time in FY12. The key initiative of the Translational Research Partnership Award is to encourage partnerships between clinicians and laboratory scientists that will accelerate the movement of promising ideas in lung cancer into clinical applications.
Pre-Application Deadline: May 30
Application Deadline: September 20
The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high risk/high reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.
Deadline: June 1
Race for the Place- Join Our Team!
The Race for the Place, an event that benefits the Gathering Place, will be held Sunday, June 3 at Beachwood Place Mall. The Case CCC has created a CaseCCC Trainees team. Clickhere to join the team or to show your support by making a donation. Contact Lyn Haselton, Case CCC Training Program Manager, at 216.844.5375 or firstname.lastname@example.org for more information.
CWRU Launches New Data Management Website
Information Technology Services (ITS) has launched a website designed to assist researchers with planning for and executing the complex task of managing project data. TheData Management website contains resources and recommendations from the university, other research institutions, the NSF and the NIH. As a service to the research community as they develop project proposals, data management and data sharing plans, ITS has equipped the site with NIH, NSF and government agency requirements, guidelines on how to write individual plans, examples of plan proposals, and Data Repository information.
NCI CANCER BULLETIN
April 17, 2012
Featured Article: Targeted Nanoparticle Tested in Patients with Cancer
Many Patients with Cancer Need Better Treatments for Pain
More Chemotherapy May Help after Initial Treatment for Childhood Leukemia Fails
For Older Patients with Leukemia, Low Doses of Gemtuzumab Improve Survival
A Conversation with Dr. Lowell Schnipper about Cancer Care and the Choosing Wisely Campaign
Norwegian Study Estimates Overdiagnosis of Breast Cancer from Screening
Using Imaging to Pinpoint Genetic Mutations in Brain Tumors
Featured Clinical Trial: Testing Vascular Disruption Combined with Chemotherapy for Advanced Solid Tumors
**All events are open to anyone interested in attending
Pathology Research Seminar Series
Brian Rubin, MD, PhD
Associate Professor, Anatomic Pathology
Topic: A Disease-defining Gene Fusion in Epithelioid Hemangioendothelioma
12 pm WRB 1-413
Sequencing Data Interest Group (SDIG)
Bo Hu, PhD
Assistant Staff, Quantitative Health Sciences
Topic: Some Statistical Issues in Analyzing Next Generation Sequencing Data
2:30 pm WRB 1-402
Hematology and Oncology Division Research Conference
Anita Schwandt, MD
Fellow, Div. of Hem/Onc
Topic: Research: Endometrial Cancer: The Role of Chemotherapy and Radiation Therapy
8 am Lerner Tower B-151
Immunology Invited Speaker Seminar Series
John Cambier, PhD
Distinguished Professor and Chair, Immunology
University of Colorado
Topic: Loss of B cell Anergy in Physiologic Context: Mechanisms and Auto Immune Consequences
12 pm NC1-202 Cleveland Clinic
Frontiers in Biological Sciences Lecture Series
Eric J. Nestler, MD, PhD
Mt. Sinai Medical School
Topic: Transcriptional and Epigenetic Mechanisms of Addiction
George Koob, PhD
Scripps Research Institute
Topic: Neurocircuitry of Addiction: View from the Dark Side
Linda Bauer Cottler, PhD, MPH
University of Florida
Topic: Bringing Light to the Dark: The Community View
1:30-5 pm SOM E501
Molecular Cardiology Faculty Seminar Series
Ellen Chien, PhD
Biochemistry and Molecular Biology
University of Chicago
Topic: G-Protein Coupled Receptors from Expression to Structure
3 pm NC1-202 Cleveland Clinic
Molecular Biology and Microbiology Seminar
Kristine Potter, PhD
Wise Lab, Molecular Biology and Microbiology
Topic: A Dominant Role for Polyadenylation in the Forkhead Transcription Factor-Mediated Regulation of Meiotic Cyclin Gene
1 pm SOM W203
Terri Gula, MD
Fellow, Div. of Hem/Onc
Topic: Novel Agents in the Treatment of Multiple Myeloma
8 am Wearn 137
Taussig Cancer Institute Grand Rounds
Rahul Tendulkar, MD
Associate Staff, Radiation Oncology
Topic: Risk Stratification in Breast Cancer and Prostate Cancer
8 am R3/002-003 Cleveland Clinic
Cell Biology Seminar Series
Alex Stegh, PhD
Assistant Professor, Neurology
Northwestern University/Robert H. Lurie Comprehensive Cancer Center
Topic: Bcl-2 Proteins, MicroRNAs, and Nanotechnology: Defining and Overcoming Therapy Resistance in Malignant Glioma
10 am NC1-202 Cleveland Clinic
Cancer Center Seminar Series
Peter Scacheri, PhD
Assistant Professor, Genetics and Genome Sciences
Topic: Variant Enhancer Loci in Cancer
12 pm BRB 105
Cancer Center Research in Progress Seminar
Yujun Hao, PhD
Postdoctoral Scholar, Wang Lab, Genetics
Topic: Gain of Direct Interaction With IRS1 By the Helical Domain Mutations of p110 Alpha Is Crucial For Their Oncogenic Function
4 pm WRB 3-136
Case CCC Calendar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
Case GI Cancers SPORE Retreat
May 4 Dively Building
Details and Agenda
Breast Cancer 2012: Risk Assessment through Survivorship
Case CCC Scientific Series: Imaging Research
Jim Basilion, PhD
Chris Flask, PhD
Topic: Development of PARACEST-MRI Imaging Agents for In Vivo Assessment of Autophagy OR Magnetic Resonance Imaging as an Early-Stage Biomarker
Cheryl Thompson, PhD
Topic: Variation in Breast Tissue Gene Expression by Mammographic Density
Reception and presentations, 4-6 pm WRB 1-413
Ca-PRI Annual Meeting: Learning from Our Differences
June 5-7 InterContinental Hotel
ADDITIONAL UPCOMING SEMINARS & EVENTS
Department of Biomedical Engineering Special Seminar
Steve Zullo, PhD
Program Director, Division of Discovery Science and Technology
National Institute of Biomedical Imaging and Bioengineering, NIH
Topic: NIH Grant Machine Revealed, Not a Black Box Anymore
12 pm Wickenden 509